Change in classification of COVID-19 testing devices: Notice to industry

This notice is to inform manufacturers, importers and distributors of the change in classification of COVID-19 testing devices.

On this page

Background

During the COVID-19 pandemic, SARS-CoV-2 was considered a life-threatening disease with high transmission risk. An accurate diagnosis was critical to reducing public health impacts.

In response, Health Canada:

Since the pandemic, the scientific evidence, risk profile of the disease and public health context have evolved. We have thus re-evaluated the classification of these devices in line with the classification rules in Schedule 1 of the regulations. We have updated the classification to help keep regulatory oversight in proportion to the medical device's risk.

About the classification change

As of March 18, 2026, COVID-19 testing devices are classified as follows:

The classification of multiplex testing devices and analyzers that can detect other diseases may also be impacted. The classification of these devices will follow the highest-risk component detected (Schedule 1, Part 2, Rule 7).

The new classification applies to all COVID-19 testing devices currently authorized or licensed for sale under the regulations. This includes multiplex tests and analyzers where applicable.

Implementing the classification change

The new classification does not impact a manufacturer's ability to import and sell their authorized or licensed device.

No action is required from applicants, authorization or licence holders at this time.

We will contact:

All new applications for medical device licences should reflect the updated classification.

For information on submitting an application, consult:

Contact us

If you have questions about this notice, contact the Medical Devices Directorate at meddevices-instrumentsmed@hc-sc.gc.ca.

Page details

2026-03-18